A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the qualifying studies with CP-690,550 providing entry criteria is met.
Checked against the public recordLast updated Jun 26, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Pfizer
- Interventions being studied
- Drug: CP-690,550; Drug: CP-690,550
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Have participated in qualifying study with CP-690,550 and are 18 years or older with diagnosis of plaque-type psoriasis (psoriasis vulgaris). Exclusion Criteria: * Non-plaque or drug induced forms of psoriasis; * Cannot discontinue current oral, injectable or topical therapy for psoriasis or cannot discontinue phototherapy (PUVA or UVB). * Any uncontrolled significant medical condition.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Radiant Research, Inc.Birmingham, Alabama
- UAB DermatologyBirmingham, Alabama
- Horizon Research Group, Inc.Mobile, Alabama
- Radiant Research, Inc.Tucson, Arizona
- Burke Pharmaceutical ResearchHot Springs, Arkansas
- Bakersfield Dermatology and Skin Cancer Medical GroupBakersfield, California
- Associates In Research, Inc.Fresno, California
- University of California IrvineIrvine, California
- Dermatology Research AssociatesLos Angeles, California
- Dermatology Specialists, Inc.Oceanside, California
- MedDerm AssociatesSan Diego, California
- UCSD DermatologySan Diego, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 26, 2017. Always confirm current availability with the study team.